The targeting construct was designed to insert a loxP-flanked neomycin (neo) resistance cassette downstream of exon 13 of the gene. A point mutation, M425A, is introduced in exon 13, which encodes a key residue for determining the selectivity of PKC inhibitors. Cre-mediated recombination removed the floxed neo cassette.